Tocilizumab, an IL-6 blocking biologic, showed efficacy in sJIA (89–91) and is currently being repositioned for use in the treatment of AIDs, but its efficacy in AID is lower than that of IL-1 blockers (92). This evidence concerns the gene IL1A and AIDS.